Z. Mostafavi-Pour, N. Jamali, Javad Saffari-Chaleshtori, Mohammad Samare-Najaf
{"title":"The effect of metformin on Bad, Bak, and Bim pro-apoptotic factors: A molecular dynamic simulation study","authors":"Z. Mostafavi-Pour, N. Jamali, Javad Saffari-Chaleshtori, Mohammad Samare-Najaf","doi":"10.2174/1573394718666220930143651","DOIUrl":null,"url":null,"abstract":"\n\nRecent investigations have demonstrated that metformin treatment can decrease tumor incidence and growth using cell cycle arrest and induction of apoptosis pathway. However, it is not clear how metformin affects the factors involved in the apoptotic process.\n\n\n\nThe present study aimed to determine the effect of metformin on Bak, Bad, and Bim pro-apoptotic proteins using docking and dynamics simulation studies.\n\n\n\nThe 3D structure of molecules was retrieved from PubChem and RCSB servers. Simulation and docking studies were conducted by Gromacs and AutoDock software. Next, molecular dynamics analysis was performed using Gromacs software. Moreover, LigPlot+V.4.5.3 software was applied for the determination of the hydrogen and hydrophobic interactions at the binding sites.\n\n\n\nOur findings demonstrated that metformin has the highest affinity for binding the Bak protein. This binding occurred using four amino acid residues within the binding site of Bak with the minimum binding energy (-5.70 kcal/mol). The molecular docking of metformin to these pro-apoptotic factors significantly decreased the total energy and increased the coil secondary structure of Bak protein.\n\n\n\nAccording to our findings, metformin can alter the molecular dynamics property of these proteins which results in increased activity of these pro-apoptotic proteins and induction of apoptosis.\n","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cancer Therapy Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573394718666220930143651","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Recent investigations have demonstrated that metformin treatment can decrease tumor incidence and growth using cell cycle arrest and induction of apoptosis pathway. However, it is not clear how metformin affects the factors involved in the apoptotic process.
The present study aimed to determine the effect of metformin on Bak, Bad, and Bim pro-apoptotic proteins using docking and dynamics simulation studies.
The 3D structure of molecules was retrieved from PubChem and RCSB servers. Simulation and docking studies were conducted by Gromacs and AutoDock software. Next, molecular dynamics analysis was performed using Gromacs software. Moreover, LigPlot+V.4.5.3 software was applied for the determination of the hydrogen and hydrophobic interactions at the binding sites.
Our findings demonstrated that metformin has the highest affinity for binding the Bak protein. This binding occurred using four amino acid residues within the binding site of Bak with the minimum binding energy (-5.70 kcal/mol). The molecular docking of metformin to these pro-apoptotic factors significantly decreased the total energy and increased the coil secondary structure of Bak protein.
According to our findings, metformin can alter the molecular dynamics property of these proteins which results in increased activity of these pro-apoptotic proteins and induction of apoptosis.
期刊介绍:
Current Cancer Therapy Reviews publishes frontier reviews on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.